Ultra-Low-Dose Rituximab for the Treatment of Refractory Pemphigus Vulgaris with a History of Treated Pulmonary Tuberculosis: A Case Report
- 1Department of Dermatology
Abstract
Fangyan Zhou, Chengyao Zhu Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, People’s Republic of ChinaCorrespondence: Chengyao Zhu, Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, N1 Shangcheng Avenue, Yiwu, 322000, People’s Republic of China, Email [email protected]: Pemphigus, a common autoimmune bullous disorder, imposes a significant clinical and socioeconomic burden on affected individuals. In addition to corticosteroids and immunosuppressants, standard-dose rituximab is now widely used in clinical practice for the treatment of moderate-to-severe pemphigus. However, the optimal dosing strategy of rituximab for patients with a history of treated pulmonary tuberculosis remains unclear. Herein, we report a case of refractory pemphigus vulgaris with a history of treated tuberculosis, successfully managed with ultra-low-dose rituximab in combination with corticosteroids and immunosuppressants. During the 6-month follow-up, the Pemphigus Disease Area Index score continued to decrease.Keywords: rituximab, pemphigus vulgaris, autoimmune bullous diseases, pulmonary tuberculosis, autoimmunity
Related
- Successful Treatment with Rituximab in a Patient with Clinically Suspected Small-vessel Primary Central Nervous System Vasculitis Refractory to Cyclophosphamide Pulse Therapy
- PO048 | EFFICACY OF RITUXIMAB TREATMENT IN A CASE OF A RELAPSED AND REFRACTORY ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA
- Determinants of Anticipated Video-Supported Treatment Acceptability in Drug-Susceptible Pulmonary Tuberculosis
- Synergistic Activity of Venetoclax and Rituximab in Multiply Relapsed or Refractory Waldenström Macroglobulinaemia
- SERPINC1-mediated hereditary antithrombin deficiency with refractory pulmonary embolism: successful treatment with VA-ECMO and interventional thrombus aspiration
BibTeX
@article{zhou2026ultralowdose,
title = {{Ultra-Low-Dose Rituximab for the Treatment of Refractory Pemphigus Vulgaris with a History of Treated Pulmonary Tuberculosis: A Case Report}},
author = {Zhou F and Zhu C},
journal = {Clinical, Cosmetic and Investigational Dermatology},
year = {2026},
month = nov,
url = {https://www.dovepress.com/ultra-low-dose-rituximab-for-the-treatment-of-refractory-pemphigus-vul-peer-reviewed-fulltext-article-CCID},
note = {CC BY},
}
RIS
TY - JOUR
TI - Ultra-Low-Dose Rituximab for the Treatment of Refractory Pemphigus Vulgaris with a History of Treated Pulmonary Tuberculosis: A Case Report
AU - Zhou F
AU - Zhu C
PY - 2026
DA - 2026/11/08
JO - Clinical, Cosmetic and Investigational Dermatology
UR - https://www.dovepress.com/ultra-low-dose-rituximab-for-the-treatment-of-refractory-pemphigus-vul-peer-reviewed-fulltext-article-CCID
AB - Fangyan Zhou, Chengyao Zhu Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, People’s Republic of ChinaCorrespondence: Chengyao Zhu, Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, N1 Shangcheng Avenue, Yiwu, 322000, People’s Republic of China, Email [email protected]: Pemphigus, a common autoimmune bullous disorder, imposes a significant clinical and socioeconomic burden on affected individuals. In addition to corticosteroids and immunosuppressants, standard-dose rituximab is now widely used in clinical practice for the treatment of moderate-to-severe pemphigus. However, the optimal dosing strategy of rituximab for patients with a history of treated pulmonary tuberculosis remains unclear. Herein, we report a case of refractory pemphigus vulgaris with a history of treated tuberculosis, successfully managed with ultra-low-dose rituximab in combination with corticosteroids and immunosuppressants. During the 6-month follow-up, the Pemphigus Disease Area Index score continued to decrease.Keywords: rituximab, pemphigus vulgaris, autoimmune bullous diseases, pulmonary tuberculosis, autoimmunity
SN - 1178-7015
ER -